Skip to main content
PLOS One logoLink to PLOS One
. 2024 Mar 14;19(3):e0300251. doi: 10.1371/journal.pone.0300251

Major depressive disorder and irritable bowel syndrome risk: A Mendelian randomization study

Guowei Sun 1, Yueyi Jiang 2,*
Editor: Bo Hu3
PMCID: PMC10939280  PMID: 38483921

Abstract

Background

Previous studies have revealed a connection between major depressive disorder (MDD) and irritable bowel syndrome (IBS), but it remains obscure if the two diseases are related causally. Mendelian randomization was utilized in this investigation to ascertain whether MDD contributed to the emergence of IBS.

Methods

To examine possible connections between MDD and IBS, we used two-sample Mendelian randomization (MR) utilizing summary data from genome-wide association studies (GWAS). The Psychiatric Genomics Consortium (PGC) provided information on genetic associations with MDD (cases: 135,458; controls: 344,901). The Medical Research Council Integrative Epidemiology Unit (MRC-IEU) provided information on genetic associations with IBS (cases:10,939; controls:451,994). Inverse Variance Weighted (main analyses), MR-Egger regression, Weighted mode, and Weighted Median were the four MR methods used in this investigation. In addition, we also performed multiplicity and heterogeneity analyses to eliminate possible biases.

Results

In the standard Inverse Variance Weighting (IVW) method, an increased risk of IBS was linked to a genetic susceptibility to MDD (OR: 1.01; 95% CI: 1.006 to 1.014, p = 1.02E-07). In addition, neither significant heterogeneity (IVW Q = 24.80, p = 0.73) nor horizontal pleiotropy (MR Egger p = 0.17; MRPRESSO p = 0.54) were detected in this MR analysis. The bidirectional analysis, however, did not show a genetic link between IBD and MDD (p steiger <0.01).

Conclusion

A direct causal relationship between MDD and IBS was revealed by Mendelian randomization study, which contributes to the effective clinical management of both diseases.

1. Introduction

Major depressive disorder (MDD), which has a lifetime prevalence of 15–30%, is a very common mental health condition that is predominantly characterized by depressed mood, decreased interest, ruminative thoughts, loss of pleasure, feelings of guilt or worthlessness, decreased energy, poor cognition, vegetative symptoms, and suicidal attempts. About twice as many women as males have MDD, and MDD affects above 6% of the global adult population every year [1]. Irritable bowel syndrome (IBS) symptoms are prevalent in those who have been given a diagnosis of depressive disorders, according to reports [2, 3]. Irritable bowel syndrome (IBS), one of the most prevalent functional gastrointestinal disorders, is characterized by abdominal pain, bloating, and changes in bowel patterns (constipation, diarrhea, or both), but there are no known structural abnormalities [4]. The total prevalence of IBS in the world is 11.2% [57].

Both MDD and IBS have been reported to cause significant physical and psychological harm to a significant population. Many patients have a significant decline in quality of life, and society bears a hefty financial burden [8, 9]. Irritable bowel syndrome, a major public health problem, can have a significant financial burden. According to a systematic study released in 2013, the cost of irritable bowel syndrome treatment ranges from $1,562 to $7,547 per year for direct costs and from $791 to $7,737 annually for indirect costs in the United States [10]. Not only that, but IBS also results in humanistic burdens including reduced personal quality of life, decreased socialization and insufficient rest [11].

A link between IBS and MDD has been suggested by earlier investigations. A cross-sectional study that was conducted more recently on the incidence of IBS symptoms in patients with MDD discovered that these patients had higher rates of IBS symptoms than those in the control group [12]. However, the relationships between genetic and environmental exposures and other potential confounding factors in human observational research also present a number of additional difficulties. Thus, understanding the connection between the two concurrent disorders may be of utmost importance to public health as a result of the disputed causal association between MDD and IBS.

MR is a useful method for assessing causal relationships, which has the advantage of using genetic variation known as single nucleotide polymorphism (SNP), which is randomly assigned at conception, thus exactly simulates the randomization process of randomized controlled trials, so as to eliminating environmental exposure, socio-economic conditions, behavior and reverse causality and other confounding variables [13, 14].

In order to determine whether there is a causal connection between the two diseases, we first hypothesized that IBS might be a downstream effect of MDD. We then chose SNPs from GWAS and used two-sample MR (TSMR), a technique that does not require individual-level data, to infer the relationship.

2. Methods

Mendelian randomization and assumptions

Our study utilized the TSMR method to examine the relationship between MDD and IBS. We based our MR analysis on three fundamental hypotheses (Fig 1): (1) Correlation hypothesis: The chosen genetic variant should demonstrate a strong association with the exposure variable. Weak instruments may result in biased estimates; (2) Independence hypothesis: This hypothesis suggests that the genetic variant used as an instrument for the exposure variable is associated with the outcome solely through its impact on the exposure, without any alternative pathway involvement. In essence, the genetic variant should not be linked to any confounders of the exposure-outcome relationship; (3) Exclusion hypothesis: This hypothesis asserts that the genetic variant used as an instrument influences the outcome exclusively through its effect on the exposure, without involvement in any other pathway. Violation of this assumption, such as pleiotropy (wherein the genetic variant affects multiple phenotypes), can lead to biased estimates. In traditional observational studies, confounders are variables associated with both the exposure and outcome of interest. Failure to properly control for confounders can result in biased estimates of the exposure-outcome relationship. Mendelian randomization mitigates confounding factors by employing genetic variants as instrumental variables (IVs). These IVs are randomly allocated during meiosis and are less susceptible to environmental or lifestyle influences. This approach mimics a randomized controlled trial, leveraging the natural randomization of genetic inheritance to reduce bias from confounding variables.

Fig 1. Diagram of the Mendelian randomization assumptions supporting a two-sample Mendelian randomization analysis of the causal effect of major depressive disorder on irritable bowel syndrome.

Fig 1

Data resources

The Psychiatric Genomics Consortium (PGC) is recognized as a pioneering initiative in psychiatry, fostering collaboration and accelerating progress in unraveling the genetic basis of psychiatric disorders. With over 800 investigators spanning 36 countries and a participant cohort exceeding 400,000 individuals, the PGC represents a global effort to advance mental health research. The SNPs related to MDD were identified from the 135,458 patients and 344,901 population controls in the Psychiatric Genomics Consortium (PGC) (PGC—Psychiatric Genomics Consortium (unc.edu)). The Medical Research Council (MRC) Integrative Epidemiology Unit at the University of Bristol (MRC IEU) aims to integrate molecular, cellular, clinical, and population data to identify causal associations between modifiable exposures and health outcomes. Employing a multidisciplinary approach, the Unit addresses key public health issues pertinent to both the UK and global agendas. By leveraging disciplines beyond traditional epidemiology, the MRC IEU enhances causal and translational epidemiology. The SNPs linked to IBS were found in the Medical Research Council Integrative Epidemiology Unit (MRC-IEU) (MRC Integrative Epidemiology Unit—UKRI) dataset of 10,939 patients and 451,994 controls (S1 Table). In the analysis to study the causal impact of MDD on IBD, we determined 31 single nucleotide polymorphisms (SNPs) as potential genetic instruments (S2 Table).

SNP selection

To ensure the authenticity and accuracy of the conclusions regarding the causal relationship between MDD and IBS, rigorous quality control measures were implemented to select optimal instrumental variables (IVs). Firstly, SNPs significantly associated with MDD were chosen as IVs. Two thresholds were applied for IV selection. Initially, SNPs with p-values below the genome-wide statistical significance threshold (5.00E-08) were selected to serve as IVs. Secondly, a minor allele frequency (MAF) threshold of 0.3 was applied to the variants of interest. Thirdly, adherence to one of the principles of the MR approach, which dictates that there should be no linkage disequilibrium (LD) among the included IVs, was ensured. To assess LD between the included SNPs, a clumping process was conducted (R2<0.001 and clumping distance = 10,000 kb). Fourthly, a crucial step in MR analysis is to confirm that the effects of the SNPs on the exposure align with the same allele as the effects on the outcome. To prevent distortion of strand orientation or allele coding, palindromic SNPs (e.g., those with A/T or G/C alleles) were excluded.

Mendelian randomization analyses

The inverse variance weighted (IVW) method estimates a causal effect by calculating the slope of a regression line over the associations between the weighted SNP-mean exposure and SNP-mean outcome (oriented to be positive) [15]. Statistically significant heterogeneity was considered when the Cochran’s Q test p was <0.05, the random-effects IVW model was adopted regardless of heterogeneity. In addition, a sensitivity analysis was conducted to assess potential bias resulting from directional pleiotropy or heterogeneity of individual SNP IVs. This involved employing MR-Egger regression, weighted median, and weighted mode MR methods as supplements to the IVW method [16]. MR-Egger regression can accurately estimate MR estimates in the presence of horizontal pleiotropy and quantify the degree of bias produced by this phenomenon. The intercept was utilized to determine whether directional pleiotropy has an impact on the causal estimates [17]. Weighted median method can provide a consistent MR estimate of causal influence if at least half of the instrumental variables are invalid. Weighted mode method can offer a robust causal estimate when the majority of individual estimates were from valid IVs [15]. Additionally, to identify potentially influential SNPs, which could be driven for example by horizontal pleiotropy, we performed a "leave-one-out" sensitivity analysis in which we sequentially omitted one SNP at a time. We used the funnel plot, a commonly used graphic test,to evaluate possible directional pleiotropy [18]. Finally, to eliminate the horizontal pleiotropy, we used the MR Pleiotropy Residual Sum and Outlier (MR-PRESSO) test to determine and eliminate the pleiotropic effects caused by outliers [19]. Analyses were implemented by the package TwoSampleMR (version 0.5.6) [18] and MRPRESSO (version 1.0) [19] in R (version 4.0.1). No additional ethical approval was required due to the re-analysis of previously collected and published data.

3. Results

In this study, instrumental variables (IVs) were selected using specific criteria. Single nucleotide polymorphisms (SNPs) associated with each trait at the locus-wide significance threshold (p < 5.00E-08) were considered as potential IVs to ensure a robust correlation between genetic variants and the exposure variable. LD between SNPs was evaluated using data from the 1000 Genomes Project European samples, and only SNPs with an LD value of R2<0.001 (clumping window size = 10,000kb) and the lowest P-values were retained. Additionally, SNPs with a MAF > = 0.3 were excluded to ensure the independence of the genetic variables. Ultimately, 31 statistically significant SNPs were identified from GWAS summary data for MR analysis (S2 Table).

The main analysis was conducted using the inverse variance weighted (IVW) method, which estimates a causal effect by calculating the slope of a regression line over the weighted SNP-mean exposure vs SNP-mean outcome associations (orientated to be positive). IVW proposed a causal link between MDD and IBS (OR: 1.01; 95% CI: 1.006 to 1.014, p = 1.02E-07).

Mendelian randomization is primarily used to assess causal relationships rather than directly determine the magnitude of quantitative effect sizes. While Mendelian randomization can provide insights into the direction and plausibility of the causal impact of an exposure on an outcome, it often cannot precisely measure the magnitude of this effect. Mendelian randomization utilizes genetic variants to randomly allocate exposure, mimicking the design of a randomized controlled trial. Because genetic variants are randomly assigned during the process of inheritance, their relationship with the exposure is less likely to be influenced by confounding factors. Therefore, Mendelian randomization studies can provide more reliable inference about the causal impact of exposure on the outcome. Although Mendelian randomization can offer clues about causal relationships, its results typically do not directly yield quantitative effect sizes. Assessing the magnitude of effect sizes may require incorporating other types of study designs, such as cohort studies or randomized controlled trials, to obtain more precise estimates. Thus, when interpreting Mendelian randomization study results, the emphasis is usually placed on evaluating the presence and direction of causal relationships rather than directly quantifying the size of effects.

We also performed MR-Egger, Weighted median, and Weighted mode for sensitivity analysis to verify the consistency of test results (Table 1). The MR-Egger method tested the null association hypothesis and provided an effect estimate, considering potential invalid SNPs [17]. The weighted median approach, providing a consistent estimate even with invalid SNPs [15]. The weighted mode method can offer a robust causal estimate when the majority of individual estimates were from valid IVs [15]. Method comparison plot (Fig 2) represents the results of Mendelian randomization (MR) analysis between MDD and IBS. Each data point corresponds to a SNP serving as an instrumental variable, with the accompanying line indicating the 95% confidence interval. The x-axis denotes the SNP’s effect on the exposure factor (MDD), while the y-axis indicates its effect on the outcome factor (IBS). The slope of the colored lines reflects the ratio of these effects, representing the exposure’s impact on the outcome. Different colors represent distinct algorithms. Overall, the lines exhibit an upward trend, suggesting that as MDD increases, the risk of IBS also rises. In the final step, we conducted leave-one-out sensitivity analysis to determine if the association between MDD and IBS was disproportionately influenced by any single SNP. The resulting forest plot was then examined (S2 Fig). Each black point in the forest plot represents the MR analysis (using IVW) excluding that particular SNP. Furthermore, the overall analysis including all SNPs is presented for comparison. The forest plot revealed a reliable and stable outcome, indicating that the causal effect of MDD on IBS remained consistent and was not significantly affected by excluding any single SNP.

Table 1. MR estimates from each method of assessing the causal effects of major depressive disorder on irritable bowel syndrome.

Method nSNP b se p Odds Ratio(95% CI) Q(p) Egger-intercept(p)
MR Egger 31 0.0281 0.0128 0.0368 1.03(1.003–1.055) 22.81(0.79)
Inverse variance weighted 31 0.0102 0.0019 1.02E-07 1.01(1.006–1.014) 24.80(0.73) -0.0006(0.1703)
Weighted median 31 0.0114 0.0028 3.8E-05 1.01(1.006–1.017)
Weighted mode 31 0.0165 0.0055 0.0052 1.02(1.006–1.028)

Fig 2. Scatter plots of the genetic causal associations with major depressive disorder against irritable bowel syndrome using different MR methods.

Fig 2

In order to conduct quality control, in addition to performing the leave-one out sensitivity, we also conducted horizontal polymorphism and heterogeneity analysis. The MR-Egger intercept test evaluated pleiotropy, with a significant difference from zero indicating potential horizontal pleiotropy. If SNPs influence the outcome through a pathway other than the exposure, it constitutes horizontal pleiotropy, violating Mendelian randomization (MR) assumptions. Consistent bias in MR estimates can result if the average horizontal pleiotropic effect of SNPs favors one direction. The Egger regression intercept provides an estimate of horizontal pleiotropy magnitude. We discovered no measurable evidence of horizontal pleiotropy in MR-Egger regression and MR-PRESSO analysis, which were employed to test for and account for violations of the horizontal pleiotropy assumption of Mendelian randomization (MR-Egger p = 0.17; MR-PRESSO p = 0.54). When using a fixed effect model, IVW makes the assumption that there is no horizontal pleiotropy. When using a random effect model, IVW makes the assumption that (1) the strength of association of the genetic instruments with the risk factor is not correlated with the magnitude of the pleiotropic effects and (2) the average pleiotropic effect is zero. Since there was no statistical horizontal pleiotropy, we used a fixed- effect model. Heterogeneity pertains to the variability in causal estimates obtained for each SNP, indicating the consistency of the causal estimate across all SNPs. Lower heterogeneity implies greater reliability of Mendelian randomization (MR) estimates. Heterogeneity was evaluated using each applicable MR method. Heterogeneity between SNPs was assessed using Cochran’s Q statistics. The Cochrane Q test for heterogeneity indicated that the studies are not heterogeneous. (IVW Q = 24.80, p = 0.73). The funnel plots also suggest that heterogeneity among SNPs is unlikely (S1 Fig). The aforementioned findings show that MR analysis has strong estimation and weak bias.

4. Discussion

Patients with MDD are at a significant risk for developing IBS, although the exact cause of this risk has not yet been determined. Our study is the first, as far as we are aware, to use MR analysis and large-scale GWAS data to show the causal link between MDD and IBS. Scholars have hypothesized that there is a brain gut axis through which intestine affects brain health. Our findings support past findings of observational studies that gut and brain processes interact pathophysiologically, revealing the existence of the gut-brain axis. The central and enteric neural systems communicate in both directions through the gut-brain axis, which connects the brain’s emotional and cognitive regions with the peripheral activities of the gut. The gut-brain axis, which includes the enteric nervous system, the central nervous system, the autonomic nervous system, and the neuroendocrine and neuroimmune systems, is an intricate web of linked neural connections that connect the gut and the brain [20]. Both genetic and environmental influences on brain development are mediated by it. Inspired by the brain gut axis mechanism, we conducted an extensive MR investigation to determine the cause-and-effect relationship between MDD and IBS.

The causal link between MDD and IBS was found using the four MR methods: IVW, MR-Egger regression, Weighted mode, and Weighted Median. Given that all four techniques pointed in the same way, we draw the conclusion that MDD and IBS were related causally.

Major depressive disorder (MDD) and irritable bowel syndrome (IBS) frequently occur together. It is important to clarify the causal relationship between the two diseases and to explore the underlying mechanisms, which can aid with prevention and control. On the one hand, patients with MDD should prioritize is preventing IBS. About 20% to 30% of IBS patients have comorbid MDD [21]. Between 20% and 30% of people with IBS also have concomitant MDD. About 15% of adult US citizens suffer with irritable bowel syndrome, which also contributes to up to 25% outpatient workload of a gastroenterologist [22, 23]. Thus, it is important to prevent IBS among MDD patients at the onset. On the other hand, given the co-exist of the two diseases, in clinical practice antidepressants including both tricyclic antidepressants (TCAs) and selective serotonin reuptake inhibitors (SSRIs) are usually used to treat irritable bowel syndrome, the possible pathophysiological mechanisms are alterations in serotonergic signaling or metabolism and disturbance in neurotransmitter-related control of communication between the enteric nervous system and the brain, or called "the brain-gut axis" [2224]. A potential mechanism that could explain the increased risk of IBS associated with MDD involves the activation of the cingulate region of the limbic system in the cerebral cortex. Drossman et al. utilized functional magnetic resonance imaging and observed that depression can elicit activity in this brain region [25]; Importantly, the limbic system’s emotional activity center shares the same anatomical site as the vegetative and endocrine regulatory centers, which govern digestive tract movement and secretion. Consequently, alterations in the function of these centers may occur, leading to changes in neurotransmitters and adrenocorticotropin-releasing factors. These alterations can subsequently impact visceral sensation, intestinal movement, and endocrine function. Thus, this cascade of events may contribute to the onset or exacerbation of IBS symptoms [26].

There are several limitations to our study that should be noted. Firstly, in order to minimize bias related to population stratification, our study was restricted to individuals of European ancestry, limiting the generalizability of our findings to other ancestral backgrounds. Secondly, the identification of IBS cases relied on self-reported data, which may be prone to recall bias and response bias. Additionally, the absence of individual-level data prevented us from conducting stratified analyses by potential effect modifiers such as sex, smoking, and sleep quality. Finally, although we have established a causal link between MDD and IBS, further research is needed to explore the underlying biological mechanisms and potential treatment options.

5. Conclusion

To summarize, we found that MDD significantly contributes to the emergence of IBS using Mendelian randomization study. The research findings have potential clinical significance for the care and management of IBS patients. Additionally, efforts should be made to advance the pathophysiology and therapy studies for the two disorders.

Supporting information

S1 Table. Details of the GWASs included in the Mendelian randomization.

(DOCX)

pone.0300251.s001.docx (13.1KB, docx)
S2 Table. Single SNPs used in the two- sample Mendelian randomization analysis of the causal effect of major depressive disorder and irritable bowel syndrome.

(DOCX)

pone.0300251.s002.docx (18KB, docx)
S3 Table. Leave-one-out sensitivity analysis of causal effects of major depressive disorder and irritable bowel syndrome.

(DOCX)

pone.0300251.s003.docx (19.4KB, docx)
S1 Fig. Funnel plot of single SNPs used in the Mendelian randomization analysis of the effects of major depressive disorder and irritable bowel syndrome.

(DOCX)

pone.0300251.s004.docx (196.5KB, docx)
S2 Fig. Leave-one-out sensitivity analysis for SNPs of major depressive disorder and irritable bowel syndrome.

(DOCX)

pone.0300251.s005.docx (246.9KB, docx)

Abbreviations

GWAS

Genome-Wide Association Studies

IBS

Irritable bowel syndrome

IVs

Instrumental variables

IVW

Inverse Variance Weighting

LD

Linkage disequilibrium

MAF

Minor Allele Frequency

MDD

Major Depressive Disorder

ML

Maximum Likelihood

MR

Mendelian randomization

SNPs

Single nucleotide polymorphisms

TSMR

Two-sample MR

WM

Weighted Median

Data Availability

Data including original data, figures, tables, and Supporting information files are available at: https://doi.org/10.6084/m9.figshare.25131929.v3.

Funding Statement

The author(s) received no specific funding for this work.

References

  • 1.Otte C, Gold S, Penninx B, Pariante C, Etkin A, Fava M, et al. Major depressive disorder. Nature reviews Disease primers. 2016;2:16065. doi: 10.1038/nrdp.2016.65 . [DOI] [PubMed] [Google Scholar]
  • 2.Gros DF, Antony MM, McCabe RE, Swinson RP. Frequency and severity of the symptoms of irritable bowel syndrome across the anxiety disorders and depression. J Anxiety Disord. 2009;23(2):290–6. Epub 2008/09/30. doi: 10.1016/j.janxdis.2008.08.004 . [DOI] [PubMed] [Google Scholar]
  • 3.Sibelli A, Chalder T, Everitt H, Workman P, Windgassen S, Moss-Morris R. A systematic review with meta-analysis of the role of anxiety and depression in irritable bowel syndrome onset. Psychol Med. 2016;46(15):3065–80. Epub 2016/11/03. doi: 10.1017/S0033291716001987 . [DOI] [PubMed] [Google Scholar]
  • 4.Chen J, Chen X, Xie Y, Sun Y, Wang X, Hesketh T. Irritable bowel syndrome and migraine: evidence from Mendelian randomization analysis in the UK Biobank. Expert review of gastroenterology & hepatology. 2021;15(10):1233–9. doi: 10.1080/17474124.2021.1949290 . [DOI] [PubMed] [Google Scholar]
  • 5.Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology. 2006;130(5):1480–91. Epub 2006/05/09. doi: 10.1053/j.gastro.2005.11.061 . [DOI] [PubMed] [Google Scholar]
  • 6.Mearin F, Lacy BE, Chang L, Chey WD, Lembo AJ, Simren M, et al. Bowel Disorders. Gastroenterology. 2016. Epub 2016/05/05. doi: 10.1053/j.gastro.2016.02.031 . [DOI] [PubMed] [Google Scholar]
  • 7.Palsson OS, Whitehead W, Tornblom H, Sperber AD, Simren M. Prevalence of Rome IV Functional Bowel Disorders Among Adults in the United States, Canada, and the United Kingdom. Gastroenterology. 2020;158(5):1262–73 e3. Epub 2020/01/10. doi: 10.1053/j.gastro.2019.12.021 . [DOI] [PubMed] [Google Scholar]
  • 8.Tillisch K, Chang L. Diagnosis and treatment of irritable bowel syndrome: state of the art. Current gastroenterology reports. 2005;7(4):249–56. doi: 10.1007/s11894-005-0016-y . [DOI] [PubMed] [Google Scholar]
  • 9.Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet (London, England). 2015;386(9995):743–800. doi: 10.1016/S0140-6736(15)60692-4 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Nellesen D, Yee K, Chawla A, Lewis B, Carson R. A systematic review of the economic and humanistic burden of illness in irritable bowel syndrome and chronic constipation. Journal of managed care pharmacy: JMCP. 2013;19(9):755–64. doi: 10.18553/jmcp.2013.19.9.755 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Spiller R, Aziz Q, Creed F, Emmanuel A, Houghton L, Hungin P, et al. Guidelines on the irritable bowel syndrome: mechanisms and practical management. Gut. 2007;56(12):1770–98. doi: 10.1136/gut.2007.119446 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Bardisi B, Halawani A, Halawani H, Alharbi A, Turkostany N, Alrehaili T, et al. Efficiency of diet change in irritable bowel syndrome. Journal of family medicine and primary care. 2018;7(5):946–51. doi: 10.4103/jfmpc.jfmpc_173_18 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Smith GD, Ebrahim S. ‘Mendelian randomization’: can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol. 2003;32(1):1–22. Epub 2003/04/12. doi: 10.1093/ije/dyg070 . [DOI] [PubMed] [Google Scholar]
  • 14.Smith GD, Ebrahim S. Mendelian randomization: prospects, potentials, and limitations. Int J Epidemiol. 2004;33(1):30–42. Epub 2004/04/13. doi: 10.1093/ije/dyh132 . [DOI] [PubMed] [Google Scholar]
  • 15.Bowden J, Davey Smith G, Haycock P, Burgess S. Consistent Estimation in Mendelian Randomization with Some Invalid Instruments Using a Weighted Median Estimator. Genetic epidemiology. 2016;40(4):304–14. doi: 10.1002/gepi.21965 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ (Clinical research ed). 1997;315(7109):629–34. doi: 10.1136/bmj.315.7109.629 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Burgess S, Thompson S. Interpreting findings from Mendelian randomization using the MR-Egger method. European journal of epidemiology. 2017;32(5):377–89. doi: 10.1007/s10654-017-0255-x . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Hemani G, Tilling K, Davey Smith G. Orienting the causal relationship between imprecisely measured traits using GWAS summary data. PLoS genetics. 2017;13(11):e1007081. doi: 10.1371/journal.pgen.1007081 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Verbanck M, Chen C, Neale B, Do R. Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. Nature genetics. 2018;50(5):693–8. doi: 10.1038/s41588-018-0099-7 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Borre Y, O’Malley P, Clarke G, Stanton C, Dinan T, Cryan J. Microbiota and neurodevelopmental windows: implications for brain disorders. Trends in molecular medicine. 2014;20(9):509–18. doi: 10.1016/j.molmed.2014.05.002 . [DOI] [PubMed] [Google Scholar]
  • 21.Jackson J, O’Malley P, Tomkins G, Balden E, Santoro J, Kroenke K. Treatment of functional gastrointestinal disorders with antidepressant medications: a meta-analysis. The American journal of medicine. 2000;108(1):65–72. doi: 10.1016/s0002-9343(99)00299-5 . [DOI] [PubMed] [Google Scholar]
  • 22.Ford AC, Talley NJ, Schoenfeld PS, Quigley EM, Moayyedi P. Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis. Gut. 2009;58(3):367–78. Epub 2008/11/13. doi: 10.1136/gut.2008.163162 . [DOI] [PubMed] [Google Scholar]
  • 23.Friedrich M, Grady SE, Wall GC. Effects of antidepressants in patients with irritable bowel syndrome and comorbid depression. Clin Ther. 2010;32(7):1221–33. Epub 2010/08/04. doi: 10.1016/j.clinthera.2010.07.002 . [DOI] [PubMed] [Google Scholar]
  • 24.Gershon MD. 5-Hydroxytryptamine (serotonin) in the gastrointestinal tract. Curr Opin Endocrinol Diabetes Obes. 2013;20(1):14–21. Epub 2012/12/12. doi: 10.1097/MED.0b013e32835bc703 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Drossman DA, Ringel Y, Vogt BA, Leserman J, Lin W, Smith JK, et al. Alterations of brain activity associated with resolution of emotional distress and pain in a case of severe irritable bowel syndrome. Gastroenterology. 2003;124(3):754–61. doi: 10.1053/gast.2003.50103 [DOI] [PubMed] [Google Scholar]
  • 26.Tan X, Pei W, Xie C, Wang Z, Liu J, Cheng Y, et al. Tongxie Anchang Decoction Relieves Visceral Hypersensitivity in Diarrhea-Predominant Irritable Bowel Syndrome Rats by Regulating the NGF/TrkA Signaling Pathway. Evidence-Based Complementary and Alternative Medicine. 2021;2021:1–10. doi: 10.1155/2021/6679348 [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision Letter 0

Bo Hu

13 Dec 2023

PONE-D-23-22484Major depressive disorder and irritable bowel syndrome risk: A Mendelian randomization studyPLOS ONE

Dear Dr. Jiang,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

The reviewers' comments are provided at the bottom of this email. 

Please submit your revised manuscript by Jan 27 2024 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Bo Hu, PhD

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf.

2. Did you know that depositing data in a repository is associated with up to a 25% citation advantage (https://doi.org/10.1371/journal.pone.0230416)? If you’ve not already done so, consider depositing your raw data in a repository to ensure your work is read, appreciated and cited by the largest possible audience. You’ll also earn an Accessible Data icon on your published paper if you deposit your data in any participating repository (https://plos.org/open-science/open-data/#accessible-data).

3. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information.

4. Please include a separate caption for each figure in your manuscript.

Additional Editor Comments (if provided):

Please describe the validity of the key assumptions for the MR analysis, especially the effect of potential confounders.

While the results are statistically significant, the effect size found is rather small (i.e., OR=1.01).

What are the columns of id.exposure and id.outcome in Tables S2 and S3? Please annotate them appropriately. Also, the column of sample size is not needed, which can be briefly described as a footnote.

Minor comments: (1) the MAF threshold for SNP selection should be “>=0.3” but not “=0.3”; (2) please clarify whether R2 of 0.1 or 0.001 was used for LD threshold; (2) please explain the dots in Figure 2.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: No

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: No

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The authors have explored the causal association of major depressive disorder with irritable bowel syndrome through a bidirectional mendelian randomization study. The design of this study is reasonable, and the manuscript language needs to be further adjusted before publication.

Reviewer #2: (Exclusion hypothesis) (Figs.1). Figs 1 to be written as Fig 1.

Table 1, P val or P or italicized p to be to be standardized throughout the manuscript. 95% to be written as 95% CI.

There were a number of typographical errors in the manuscript.

( Supplementary Tables S1 to be presented as (Supplementary Table S1). For year[1], the gap of the cited reference to be spaced out. This apply to others.

Labelled to be written in the first column for Table S2 and Table S3.

The sentence ‘… individual SNP IVs: MR-Egger regression….’ requires revision.

The definition of IVW could be improved e.g. The inverse variance weighted (IVW) method estimates a causal effect by calculating the slope of a regression line over the associations between the weighted SNP-mean exposure and SNP-mean outcome (oriented to be positive).

For Figure 2, the figure in X and Y axis to be labelled.

p < 5.0 x 10-8 incorrectly labelled.

The format presentation for (p < 5.0 x 10^-8) to follow the format that were presented in Supplementary Tables e.g. p <5.0E-08.

References did not conform to the journal format.

Reviewer #3: Title: Major depressive disorder and irritable bowel syndrome risk: A Mendelian randomization study

This paper utilizes Mendelian randomization to explore the potential causal relationship between major depressive disorder (MDD) and irritable bowel syndrome (IBS). Leveraging data from the Psychiatric Genomics Consortium and the Medical Research Council Integrative Epidemiology Unit, the study employs various Mendelian randomization methods, revealing a significant genetic link between MDD and an elevated risk of IBS. Rigorous analyses, including assessments for heterogeneity and bidirectionality, support the study's findings. Notably, the absence of a genetic link between inflammatory bowel disease and MDD is observed. In conclusion, the study underscores a direct causal association between MDD and IBS, offering valuable insights for clinical management. By incorporating the following change, the paper can potentially be further improved.

Abstract

1. In the Result section of Abstract author using first time IVW in the paper consider defining its full form here

IVW method � Inverse Variance Weighting (IVW) method

Introduction

1. "but there is no known structural abnormalities" might read better as "but there are no known structural abnormalities."

2. "According to a systematic study released in2013" should have a space between "in" and "2013" for proper formatting.

3. "This patients had greater rates of IBS symptoms than those in the control group" needs to be corrected to "These patients had higher rates of IBS symptoms than those in the control group."

4. “ According to a systematic study released in2013, the cost of irritable bowel syndrome treatment ranges from $1,562 to $7,547 year for direct costs and from $791 to $7,737 annually for indirect costs in the United States[10].” This sentence is not clear. Is treatment ranges from $1,562 to $7,547 per year?

Methods

The methods section provides a comprehensive approach to Mendelian randomization (MR) but could benefit from a clearer organization and improved clarity in several areas:

1. The three main hypotheses for an MR study could be presented more clearly, perhaps with a brief explanation for each, ensuring that the reader grasps their significance to the study.

2. The section on data resources is concise but consider providing a brief rationale for choosing the Psychiatric Genomics Consortium (PGC) and Medical Research Council Integrative Epidemiology Unit (MRC-IEU) datasets, highlighting their relevance to the research.

3. The criteria for SNP selection are well-defined, but it might be beneficial to provide a concise justification for these criteria and their significance in the context of the study.

4. The mention of the TwoSampleMR and MRPRESSO packages lacks supportive information or citation.

5. The phrase "version0.5.6" should have a space between "version" and the version number.

Results

1. The author states that in this study, genome-wide significant and independent SNPs were chosen as instrumental variables (IVs) for Mendelian Randomization (MR) analysis. However, the text lacks a clear explanation of how these criteria enhance the reliability of the instrumental variables. Providing a concise clarification on how the stringent criteria for significance and independence contribute to the robustness and validity of the MR analysis would strengthen the clarity and transparency of the methodology.

2. Sensitivity Analysis: Elaborate briefly on why these specific sensitivity analyses were chosen and how they contribute to the robustness of the main analysis.

3. Leave-One-Out Sensitivity Analysis: Consider incorporating a brief interpretation of the results of this analysis.

4. The inclusion of a leave-one-out sensitivity analysis is commendable, providing insight into the stability of the causal effect estimation. However, to enhance clarity, it would be beneficial to briefly define or explain what a forest map is for readers unfamiliar with the term. Additionally, consider specifying the key findings or patterns observed in the forest map that support the conclusion of a reliable and stable causal effect of MDD on IBS, even when individual SNPs are excluded. This would provide a more comprehensive and accessible interpretation of the results for a broader audience.

5. Quality control: Providing a concise explanation of each method (Horizontal polymorphism, heterogeneity analyses, and sensitivity analyses ) and their relevance to quality control would enhance transparency and the overall robustness of the study.

Discussion

The discussion provides valuable insights into the association between Major Depressive Disorder (MDD) and Irritable Bowel Syndrome (IBS) using Mendelian randomization (MR) analysis and large-scale GWAS data. It highlights the significance of the gut-brain axis in connecting gut and brain processes and suggests a causal link between MDD and IBS.

1. However, the discussion could be strengthened by incorporating references to support the mentioned hypotheses and findings. It's essential to provide citations for past studies or theories that have contributed to the understanding of the gut-brain axis and the relationship between MDD and IBS. Referencing existing literature would add credibility to the claims made in the discussion.

2. Finally, the limitations are appropriately acknowledged, but it would be beneficial to elaborate on potential biases or confounding factors that might affect the generalizability of the results. This would add nuance to the interpretation of the study's limitations.

3. The phrase "It is important to prevent IBS among MDD patients at the oneset" contains a typographical error. It should be "onset" instead of "oneset."

Conclusion

1. The discussion effectively emphasizes the clinical implications of understanding the causal relationship between MDD and IBS, advocating for prevention and control strategies. However, explicitly stating the potential clinical impact of the study's findings on patient care and management would provide a more concrete conclusion.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Shi-Yang Guan

Reviewer #2: No

Reviewer #3: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Attachment

Submitted filename: PLOS_ONE_Article_review.docx

pone.0300251.s006.docx (19.2KB, docx)

Decision Letter 1

Bo Hu

26 Feb 2024

Major depressive disorder and irritable bowel syndrome risk: A Mendelian randomization study

PONE-D-23-22484R1

Dear Dr. Jiang,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Bo Hu, PhD

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Thank the authors for addressing the comments. The quality of the paper was greatly improved. There is only one minor comment regarding space format, which can be corrected without further review.

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #2: All comments have been addressed

Reviewer #3: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #2: (No Response)

Reviewer #3: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #2: (No Response)

Reviewer #3: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #2: (No Response)

Reviewer #3: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #2: (No Response)

Reviewer #3: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #2: The authors have put in significant efforts to address the comments.

Lines 232-234, Lines 289- 297, the rows spacing is to be consistent with others.

Reviewer #3: Thank you for addressing all the concerns raised during the revision of your paper. Your efforts have significantly improved its quality and clarity.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #2: No

Reviewer #3: Yes: Sarita Poonia

**********

Acceptance letter

Bo Hu

6 Mar 2024

PONE-D-23-22484R1

PLOS ONE

Dear Dr. Jiang,

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now being handed over to our production team.

At this stage, our production department will prepare your paper for publication. This includes ensuring the following:

* All references, tables, and figures are properly cited

* All relevant supporting information is included in the manuscript submission,

* There are no issues that prevent the paper from being properly typeset

If revisions are needed, the production department will contact you directly to resolve them. If no revisions are needed, you will receive an email when the publication date has been set. At this time, we do not offer pre-publication proofs to authors during production of the accepted work. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few weeks to review your paper and let you know the next and final steps.

Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

If we can help with anything else, please email us at customercare@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Bo Hu

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Table. Details of the GWASs included in the Mendelian randomization.

    (DOCX)

    pone.0300251.s001.docx (13.1KB, docx)
    S2 Table. Single SNPs used in the two- sample Mendelian randomization analysis of the causal effect of major depressive disorder and irritable bowel syndrome.

    (DOCX)

    pone.0300251.s002.docx (18KB, docx)
    S3 Table. Leave-one-out sensitivity analysis of causal effects of major depressive disorder and irritable bowel syndrome.

    (DOCX)

    pone.0300251.s003.docx (19.4KB, docx)
    S1 Fig. Funnel plot of single SNPs used in the Mendelian randomization analysis of the effects of major depressive disorder and irritable bowel syndrome.

    (DOCX)

    pone.0300251.s004.docx (196.5KB, docx)
    S2 Fig. Leave-one-out sensitivity analysis for SNPs of major depressive disorder and irritable bowel syndrome.

    (DOCX)

    pone.0300251.s005.docx (246.9KB, docx)
    Attachment

    Submitted filename: PLOS_ONE_Article_review.docx

    pone.0300251.s006.docx (19.2KB, docx)
    Attachment

    Submitted filename: Response to Reviewers.docx

    pone.0300251.s007.docx (32.7KB, docx)

    Data Availability Statement

    Data including original data, figures, tables, and Supporting information files are available at: https://doi.org/10.6084/m9.figshare.25131929.v3.


    Articles from PLOS ONE are provided here courtesy of PLOS

    RESOURCES